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Aim To investigate the diffusion of counterfeit medicines 
in developing countries and to verify the stability of ga-
lenic dosage forms to determine the stability of galenics 
prepared and stored in developing countries.
Methods We purchased 221 pharmaceutical samples be-
longing to different therapeutic classes both in authorized 
and illegal pharmacies and subjected them to European 
Pharmacopoeia, 7th ed. quality tests. An UV-visible spec-
trophotometric assay was used to determine the galenics 
stability under different conditions of temperature (T) and 
relative humidity (RH).
Results  A  substantial  percentage  of  samples  was  sub-
standard (52%) and thus had to be considered as coun-
terfeit. Stability tests for galenics showed that the tested 
dosage forms were stable for 24 months under “standard” 
(t = 25 ± 2°C, RH = 50 ± 5%) conditions. Under “accelerated” 
(t = 40 ± 2°C, RH = 50 ± 5%) conditions, samples were stable 
for 3 months provided that they were stored in glass con-
tainers. Stability results of samples stored in “accelerated” 
conditions were similar to those obtained by on site in 
tropical countries and could so supply precious informa-
tion on the expected stability of galenics in tropical coun-
tries.
Conclusion This study gives useful information about the 
presence of counterfeit medicinal products in the pharma-
cies of many developing countries. This should serve as an 
alarm bell and an input for the production of galenics. We 
recommend setting up of galenic laboratories in develop-
ing countries around the globe.
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World  Health  Organization  (WHO)  defines  counterfeit 
drugs as medicines that are deliberately and fraudulently 
mislabeled with respect to identity and/or source. Coun-
terfeit medicines include products with correct ingredi-
ents or with wrong ingredients, without active ingredients, 
with insufficient or excessive amount of active ingredient, 
or with false or misleading labeling (1).
Counterfeits can be further classified in the following sub-
classes (2):
• “perfect”  counterfeits:  these  products  contain  the  cor-
rect active ingredient and excipients in the right amount. 
They are manufactured in foreign countries and illicitly im-
ported (parallel marketing), thus resulting in an economic 
damage.
• “imperfect” counterfeits: these products contain the right 
components, with an incorrect concentration and/or for-
mulation resulting in defective quality specifications. In the 
vast majority of cases, they are devoid of any therapeutic 
efficacy.
• “apparent” counterfeits: they are similar to the original 
product,  but  contain  non-active  ingredients  or  foreign 
substances.  Usually,  apparent  counterfeits  are  copies  of 
medicinal products that are not the only ones resolutive 
for the cure of a particular illness.
• “criminal” counterfeits: they are apparently similar to the 
original medicinal product, but do not contain any active 
ingredient and can even include harmful or toxic substanc-
es. They are usually sold at high prices and for treatment 
of serious pathologies. Consequences for users of criminal 
counterfeits can be fatal.
Counterfeit  medicines  are  widespread  in  all  countries 
around the globe and represent a major public health con-
cern, often resulting in treatment failure, serious deteriora-
tion of the state of health, or even death (3-10).
The true extent of the problem of counterfeit medicines 
is not really known, due to the fact that not every case is 
reported by competent authorities or manufacturers. The 
recent figures estimate that worldwide sales of counterfeit 
medicines reach at least US $3.5 billion per year (4). The 
phenomenon affects all pharmaceuticals, ranging from 
drugs for life-threatening diseases (eg, diabetes) to com-
mon-use analgesics or life-style products, such as drugs 
for erectile dysfunction.
The problem of counterfeits is even more serious in devel-
oping countries, where custom procedures are less strin-
gent, authorities’ controls are less effective, and the use of 
ineffective drugs may result in a substantial loss of pub-
lic confidence in the health care system (3). The principal 
target of counterfeiters are life-saving drugs. This increases 
the risk of resulting health damage, and sometimes gives 
rise to events of catastrophic proportions, like in Niger in 
1995  (when  about  60 000  people  were  injected  with  a 
counterfeit meningitis vaccine) or in Haiti in 1996 (when a 
diethylene glycol contamination of a pediatric syrup killed 
more than 80 children) (11,12).
In all developing countries, principal targets are anti-ret-
roviral drugs, antimalarics, and antibiotics, sometimes in 
staggering proportions: for instance, an international study 
published in 2004 showed that more than 53% of artesu-
nate tablets sold in southeast Asia did not contain any ac-
tive ingredient at all, with imaginable consequences on 
the fight against malaria in those countries (11,13).
According to the current European Legislation, the phar-
macist is the only professional figure lawfully entitled to 
prepare medicinal products (except, of course, pharma-
ceutical industries). As a matter of fact, the article 3 of the 
European Directive 2001/83/EC states that medicinal prod-
ucts prepared in a pharmacy in accordance with a medi-
cal prescription (magistral formula) or in accordance with 
the prescriptions of the National Pharmacopoeia (official 
formula) are exempt from marketing authorization proce-
dures applied to industrial medicinal products (14-17).
Nevertheless,  magistral  and  official  formulations  (com-
monly known as “galenics” in homage to Galen of Perga-
mum, who is regarded as the first pharmacist engaged in 
the preparation of medications) are required to be pre-
pared, labeled, and stored using standard procedures and 
established methods in order to ensure the quality of the 
finished product, which is a mandatory prerequisite for its 
safety and efficacy (18-21). The quality of galenic medica-
tions does not rely only on the professional ability and sci-
entific preparation of the pharmacist, but also on several 
external factors, such as storage conditions, chemical and 
physical  nature  of  the  active  pharmaceutical  ingredient 
(API), containers, environmental conditions, and the com-
patibility of API with excipients.
All these factors, considered as a whole, define the use-by 
date of medicinal products, which must be reported on 
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precautionary validity limits for galenics depending on the 
nature of their dosage form, leaving to the pharmacist the 
option to increase these limits based on scientific data.
We believe that galenics may considerably help in improv-
ing the health care system of developing countries essen-
tially for two reasons: the first one is that their production is 
quite cheap and the operative procedures to be followed 
are simple; the second one, most interesting and impor-
tant in our opinion, is represented by the possibility to pre-
pare medicinal products with a dosage and pharmaceuti-
cal form that can suit the local needs. Therefore, galenics 
could become an answer to a need, but their stability in 
different environmental conditions, such as those of the 
tropical  countries,  must  be  demonstrated  to  guarantee 
safety and efficacy of the therapies (22,23).
In the present article, we investigated the extent of the 
phenomenon of pharmaceutical counterfeit in developing 
countries. Our aim was to investigate the quality of medi-
cines purchased in loco from pharmacies or from unofficial 
street-pharmacists. The other aim was to evaluate the use-
by date of galenic dosage forms commonly prepared in 
pharmacies. This aim also gave us the opportunity to de-
termine the stability of galenics prepared and stored in de-
veloping countries, particularly those with tropical or sub-
saharian  environmental  conditions  (high  temperatures 
and relative humidity).
Methods
drugs analyzed
During our research, 221 samples were purchased and an-
alyzed; 96% of the samples were industrial drugs and 4% 
were galenics; these last were included in the analysis with 
the aim to evaluate if the quality requirements had been 
respected in Brazil, where galenics are sold by some phar-
macies as low cost medicines for poor people.
Drugs were purchased in the following countries: Ango-
la, Brazil, Cameroun, Central African Republic, Chad, Con-
go, Ethiopia, Guinea Bissau, Guinea Conakry, India, Kenya, 
Madagascar, Malawi, Rwanda, and Uganda. Samples were 
purchased both in official pharmacies and from unauthor-
ized  street  pharmacists.  The  tested  medicinal  products 
were chosen, in agreement with local medical doctors, be-
tween those more used for endemic diseases. The active 
pharmaceutical ingredients evaluated in this study were 
above all antibiotics and anti-inflammatories, formulated 
as tablets and capsules, because these are the prevalently 
administered pharmaceutical forms (Tables 1 and 2).
For each test item, the country of origin and the declared 
manufacturing site were noted; samples were thus sub-
jected to the analyses reported in the Table 3. Obviously, 
disintegration, friability, and hardness assays were applied 
only to tablets. The analyses were performed in the labora-
tories of the Department of Science and Technology (Fac-
ulty of Pharmacy, University of Turin, Italy). Each assay was 
carried out using instruments and methods in compliance 
with the relative monograph of the Official Pharmacopoe-
ia of the European Union (Ph. Eur. 7 ed.) (17).
Standard reagents (Carlo Erba, Rodano, Italy) and labware 
were used. To determine the uniformity of content, a UV-
visible (UV-VIS) spectroscopic method was used to quan-
tify the active pharmaceutical ingredient in each dosage 
form (using a DU 730 spectrophotometer, Beckman, Mi-
lan, Italy). For each active pharmaceutical ingredient con-
tained in the dosage forms, a suitable solvent was chosen 
for UV-VIS analysis. The wavelength of maximum absor-
tABle 1. therapeutic classes of total and counterfeit samples
No. (%) of samples
therapeutic classes available for analysis counterfeit
Antibiotics 76 (34.4) 30 (29.7)
Anti-inflammatories 44 (19.9) 22 (21.8)
Antipyretics 24 (10.9)   9 (8.9)
Antimalarics 17 (7.7)   6 (5.9)
Antimycotics 13 (5.9)   9 (8.9)
Antihypertensives   8 (3.6)   1 (1.0)
Antianemics   5 (2.3)   4 (4.0)
Spasmolytics   5 (2.3)   2 (2.0)
Diuretics   5 (2.3)   1 (1.0)
Antiacids   5 (2.3)   2 (2.0) 
Bronchodilators   4 (1.8)   5 (5.0)
Others 15 (6.8) 10 (9.9)
tABle 2. Quantity of different dosage forms of the samples
dosage forms samples available for analysis
Ointments   1
Effervescent tablets   2
Creams   2
Gastro-resistant tablets   3
Oral powders   4
Vials   9
Coated tablets   21
Capsules   40
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bance (λmax), when not available in literature (24) was de-
termined  by  analyzing  the  UV  spectrum  between  200 
and 600 nm.
Since all these assays were mandatory to ensure the qual-
ity of a dosage form, it was sufficient to obtain an out-of-
specification (OOS) value in one of these to classify it as 
a counterfeit medicine. Since the quali-quantitative con-
tent of excipients was unknown in most cases, it was not 
possible to prepare a proper blank solution for test items; 
anyhow, since the comparison was made within the same 
dosage forms, the interferences due to excipients were 
minimized using solvents in which they, usually lipophilic, 
are almost insoluble.
Analytical method validation
Several publications, also regarding counterfeits, propose 
high performance liquid chromatography (HPLC) as a suit-
able method for medicinal product analysis (24-30). Taking 
into account that Pharmacopoeia (17) does not prescribe 
a specific analytical method for performing the content 
uniformity assay (simply stating that a “suitable analytical 
method” should be applied), we decided to use an UV-VIS 
spectrophotometric method. This choice was also deter-
mined by an opportunity to apply this technique in African 
countries, where the instruments necessary for HPLC are 
too expensive. In any case, in order to evaluate the equiva-
lence between the two methods, every sample containing 
amoxicillin, ibuprofen, and paracetamol was analyzed us-
ing both HPLC and UV-VIS methods and the results were 
compared.
stability study
Eight galenics were formulated in seven different dosages 
at the laboratory of A.P.P.A.® Project, the main project of 
Aid Progress Pharmacist Agreement, a no-profit organiza-
tion proposing to assist the realization of galenic labo-
ratories in developing countries around the globe.
The A.P.P.A.® Project is usually performed in different phas-
es, detailed on the Web site www.progettoappa.it. A pre-
liminary need of the Project is to determine (through on-
site sampling) the average quality of available medicines 
in the area, to ascertain the percentage of substandard or 
counterfeit drugs, and to set up a priority list with the most 
problematic realities on the top. Therefore, a preliminary 
stability study on the most common and used pharmaceu-
tical forms was performed. When the galenic laboratory is 
set up, the galenics produced in the laboratory are sent to 
A.P.P.A.® staff in Turin for a quality check to ensure that a suf-
ficient quality level is continuously maintained. The quali-
quantitative composition of the analyzed galenics was re-
ported in Table 4 (18,20,21). For each galenic dosage form, 
the complete dosage form and its API was tested.
Two different batches of samples were prepared: the first 
one was prepared 18 months prior to the beginning of the 
tABle 3. Assays from european Pharmacopoeia for quality and assurance control
Analysis Method of reference Acceptance criteria
General aspect Visual Posological unit integrity
Uniformity of content Assay 2.9.6 Each individual content is between 85% and 115% of the average content (10 dosage units)
Uniformity of mass Assay 2.9.5 Not more than two of the individual masses deviate from the average mass by more than 
±10% and none deviates by more than ±20% (20 dosage units)
Disintegration Assay 2.9.1 At the end of the specified time all of the dosage units must have disintegrated completely
Friability Assay 2.9.7 Maximum loss of mass not more than 1%
Hardness Assay 2.9.8 Hardness between 4 and 10 N
tABle 4. Quali-quantitative composition of tested galenics 
prepared in A.P.P.A.® laboratories
Active pharmaceutical 
ingredient
dosage 
form
Quali-quantitative 
composition
Paroxetine Capsules Paroxetine 20 mg
Starch 380 mg
Amoxicillin Tablets Amoxicillin 500 mg
250 mg excipients 
(see below)
Mix:
Polyethylene glycol 4000 5%
Magnesium stearate 4.5%
Talcum powder 4.5%
Corn starch 32%
Microcristalline cellulose 54%
Hydrocortisone acetate Cream Hydrocortisone acetate 
0.5% in base cream
Ketoprofen Gel Ketoprofen 5% in base gel
Dextromethorphan 
hydrobromide
Oral drops Dextromethorphan 1.5% in 
poliolic vehicle
Nifedipine Capsules Nifedipine 20 mg
Starch 430 mg
Fluoxetine Capsules Fluoxetina 20 mg
Starch 430 mg177 Baratta et al: Diffusion of counterfeit drugs and stability of galenics
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study and stored at “standard” conditions (as hereinafter de-
fined). A second batch of samples was prepared at the be-
ginning of the stability study and used as a standard to check 
the stability of the first batch after 18 months’ storage.
All samples of dosage forms (in a sufficient amount to al-
low sampling through the whole study) were stored in cali-
brated thermostats. Samples of the relative powdered APIs 
were stored at the same conditions and analyzed in paral-
lel with finished dosage forms. Three different conditions 
of  temperature  (T)  and  relative  humidity  (RH),  ie, “stan-
dard,” “accelerated,” and “stress” conditions, were applied to 
all samples (31,32). The “standard” conditions (t = 25 ± 2°C, 
RH = 50 ± 5%) were applied to define the stability of sam-
ples under pharmacy storage conditions accepted by the 
European Pharmacopoeia.
“Accelerated”  (t = 40 ± 2°C;  RH = 50 ± 5%)  and  “stress” 
(t = 40 ± 2°C;  RH = 80 ± 5%)  conditions  were  investigated 
with a double purpose: to support real-time stability data 
with the results coming from accelerated storage condi-
tions and to obtain information on the expected stability 
of drugs in tropical climates. For samples stored in “acceler-
ated” and “stress” conditions, both polypropylene (PP) and 
glass containers were used, while samples under “standard” 
conditions were stored only in PP containers.
Chemical stability both of dosage forms and APIs was eval-
uated by a quantitative assay at different time points dur-
ing the overall 6-month study period. For “standard” condi-
tions, two sampling time points were foreseen, T0 and T6. 
For “accelerated” and “stress” conditions, further sampling 
time points were foreseen on a monthly basis. Both for APIs 
and dosage forms, 10 samples were analyzed at each time 
point and the average API concentration was calculated as 
the arithmetic mean of all values.
We took into account “stress” and “accelerated” conditions 
to gather information on the prospective stability of ga-
lenics in extreme environmental conditions (eg, in tropical 
countries). Eventually, we compared the stability data of 
galenics stored in PP and glass containers. As foreseen by 
the pharmacopoeia, samples complied with specifications 
if the API content was within ±10% of the expected value.
Analytical method
The UV-VIS spectrophotometric assay used to determine 
the samples stability was the same as described before 
(17,24,33). In addition, a calibration curve was prepared at 
λmax for each API and the concentration in each sample at 
different time points was calculated using Lambert-Beer’s 
law (A = εbc).
For the analysis of APIs contained in the dosage forms, a 
second calibration curve was obtained by using standard 
solutions prepared mixing API and excipients in the same 
ratio used for the dosage forms. This was done in order to 
avoid underestimating the samples concentration due to 
an incomplete API extraction from the excipients matrix.
Blank solutions were prepared by dissolving appropriate 
amounts of excipients contained in the pharmaceutical 
forms in suitable solvents. Analytical samples were extract-
ed from dosage forms using an appropriate amount of sol-
vent and favoring the dissolution with a vortex. After cen-
trifugation for 5 minutes at 4000 rpm, supernatants were 
properly diluted using the same solvent for spectrophoto-
metric analysis. Isolated APIs were dissolved in solvent at 
an appropriate concentration and analyzed directly.
Results
Counterfeit drugs
Central African Republic was excluded from the final evalu-
ation due to an insufficient number of samples. Thus, the 
presented results correspond to 196 samples instead of 
221 (Figure 1). The most represented manufacturing coun-
try was India (31%), but it is noteworthy that in 56% of the 
cases it was not possible to determine the manufacturing 
country (Figure 2).
The overall percentages of samples satisfying Pharmaco-
poeia assays were the following: general aspect 96%, uni-
formity of mass 95%, uniformity of content 75%, disinte-
gration 90%, hardness 74%, and friability 85%. Based on 
these results, it was possible to determine that 50% of test 
items were substandard drugs and even 2% were counter-
feits without the presence of the declared API, ie, criminal 
counterfeits (Figure 3). Our results also showed that Indian 
drugs were often substandard: 30 out of 61 Indian samples 
(ie, 41.7%) showed OOS values. Only for 109 samples out of 
221, it was possible to determine whether they were pur-
chased in pharmacies (83%) or from unofficial street-phar-
macists (17%). The percentage of counterfeit products was 
greater in the case of street-pharmacists (Figure 4).
The overall distribution of counterfeits and substan-
dard medicines in different countries showed that PHARMACOLOGY  178 Croat Med J. 2012;53:173-84
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the  countries  mostly  affected  by  counterfeiting  were 
Rwanda and Guinea Conakry, where more than 70% of the 
analyzed medicinal products were not suitable (Figure 5). 
Criminal counterfeited medicines were found in Chad, Ke-
nya, and Brazil. The results for the samples analyzed using 
both HPLC and UV-VIS spectrophotometry were uniform 
and comparable (data not shown).
Active pharmaceutical ingredient
We  stratified  the  results  to  evaluate  the  percentage  of 
counterfeit drugs concerning the three most represent-
ed active pharmaceutical ingredients in our samples, ie, 
amoxicillin, ibuprofen, and paracetamol (Figure 6).
Amoxicillin is a semi-synthetic β-lactamic antibiotic. It is 
a fundamental drug in developing countries where com-
mon infections, easily treated in developed countries, 
often claim many lives. Its synthesis, while being quite 
simple, must be carried out in a controlled environ-
ment due to the sensibility of this molecule to envi-
ronmental moisture. This problem is even more challeng-
ing in developing countries, where tropical climate and 
non-compliance with good manufacturing practices can 
dramatically hamper the quality of this antibiotic, during 
its production or during distribution and storage. We ac-
quired 24 samples of amoxicillin (both in capsules and in 
tablets), mainly from Cameroun (25%) and Chad (25%). 
As a matter of fact, uniformity of content assay was not 
satisfactory in 46% of cases, with 2 samples not contain-
ing any active ingredient at all. Moreover, other 2 samples 
had already been broken in the blister before we even 
opened it and those purchased in Angola contempora-
neously showed OOS results in three assays: uniformity of 
content, friability, and hardness.
More comforting results were obtained with uniformity 
of mass and disintegration assays, which were satisfied by 
FiGuRe 1. Country of origin of the analyzed drug samples.
FiGuRe 2. Country of production of the analyzed drug samples.
FiGuRe 3. share of counterfeit drugs in analyzed drug samples. Black 
bars – criminal counterfeit; white bars – idoneous; gray bars – imperfect 
counterfeit.
FiGuRe 4. share of counterfeit drugs sold in pharmacies vs “unofficial 
street-pharmacies.” White bars – idoneous; gray bars – imperfect coun-
terfeit.179 Baratta et al: Diffusion of counterfeit drugs and stability of galenics
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100% of the samples. Globally, 42% of samples were within 
regulatory specifications.
Ibuprofen  is  one  of  the  most  important  non-steroidal 
anti-inflammatory drugs, widely used to treat inflamma-
tory  states.  Nineteen  ibuprofen-based  drugs  were  ana-
lyzed during our study (tablets and capsules), mainly from 
Cameroun  (37%)  and  Chad  (16%).  Uniformity  of  mass 
test showed that all samples satisfied the test; uniformity 
of content gave also good results (95% of samples with-
in specifications). Disintegration and friability gave worse 
results (respectively, 11% and 16% of OOS samples). Only 
one sample showed substandard results on hardness as-
say. Sixty eight percent of samples were idoneous
Paracetamol is one of the most common-use drugs, used 
as an analgesic and antipyretic. Twenty-one samples of 
paracetamol-based  medicines  (tablets)  were  purchased, 
mainly in Cameroun (29%) and Chad (19%). Uniformity of 
content showed that 81% of samples were within speci-
fications; friability test showed that 52% of the samples 
complied with European Pharmacopoeia, 7 ed. require-
ments, and 19% of samples did not pass the hardness as-
say. Fifty-two percent of samples were idoneous.
stability study
In the laboratory of A.P.P.A.® Project, the samples of differ-
ent dosage forms were prepared as galenics with the aim 
to analyze their quality in different experimental condi-
tions that simulated tropical countries weather. Seven dif-
ferent galenic dosage samples and their APIs were stored 
for 6 months in standard conditions in PP containers. Re-
sults obtained after 6 months storage showed that all ga-
lenic dosage forms and the respective APIs could be con-
sidered stable at these conditions (active substance assay 
within ±10% of nominal value) (Table 5). Comparison of 
the results obtained from the analysis of the two batches 
of samples (prepared respectively 18 months before the 
study and at the beginning of the study) 6 months later 
demonstrated that even samples prepared 24 months be-
fore did not present any degradation or alteration. Analy-
sis in different environmental conditions (“accelerated” and 
“stress”) were in the same way performed both on samples 
prepared at the beginning and 18 months before the start 
of the study, and the results were comparable regardless 
of the storage time.
Under “accelerated” conditions, samples were stored for 6 
months at t = 40 ± 2°C, RH = 50 ± 5% in PP containers. Sam-
pling and analysis were performed on a monthly basis. 
Due to the fact that the results after 3 months showed 
marked degradation both of API and galenic dosage 
FiGuRe 5. Presence of counterfeit drugs by country. Black bars – criminal counterfeit; white bars – idoneous; gray bars – imperfect counterfeit.
FiGuRe 6. share of counterfeit drugs in selected active pharmaceuti-
cal ingredients. Black bars – criminal counterfeit; white bars – idoneous; 
gray bars – imperfect counterfeit.PHARMACOLOGY  180 Croat Med J. 2012;53:173-84
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forms, the study was interrupted at this time point (Table 
6). A similar degradation pattern emerged under “stress” 
conditions (t = 40±2°C; RH = 80±5%; data not shown).
Interestingly enough, in most cases the percentual varia-
tion of absorbance between samples and standards was 
found to be positive, pointing out the absence of API deg-
radation.
Different  causes  were  hypothesized  to  explain  this  pe-
culiarity: for instance, the high temperatures might have 
damaged the PP containers, allowing moisture to degrade 
the preparation and to alter the UV-VIS analysis. Significant-
ly, the absorbance increase was especially considerable at 
absorption wavelengths of water.
Alternatively, PP containers might have released leachable 
substances which might have interfered with the analysis. 
This last hypothesis was supported by the fact that PP con-
tainers stored under “accelerated” conditions showed color 
change after 40 days.
To confirm these hypotheses, a new subset of UV-VIS anal-
yses was designed as follows:
• water samples were stored for 3 months in PP or glass 
containers under “accelerated” conditions;
• API and galenic dosage forms were stored for 3 months in 
glass containers under “accelerated” or “stress” conditions. 
Only 4 of 7 APIs and their dosage forms were evaluated 
(paroxetine, hydrocortisone acetate, ketoprofen, and nife-
dipine).
The UV-VIS analysis of water samples stored in PP contain-
ers under “accelerated” conditions resulted in the identi-
fication of peaks not present in water samples stored in 
glass containers under the same conditions. The increase 
in the intensity of these peaks (possibly due to the con-
tamination of extractable and leachable substances from 
the PP container) was time-dependent and their absorp-
tion wavelengths corresponded to the peaks revealed in 
the stability study. These results suggest that in a hot and 
moist environment (such as in tropical countries), standard 
PP containers are not a suitable choice to store medicinal 
products and that glass containers are to be preferred.
Results obtained under “accelerated” and “stress” conditions 
on galenic samples stored in glass containers for 3 months 
showed that all samples stored under “accelerated” condi-
tions complied with the acceptability criteria after 90 days 
(APIs and dosage forms), while “stress” conditions resulted 
in substantial degradation both of APIs and dosage forms 
after 90 days (Table 7). Remarkably, the spectrum results 
were more altered for the dosage forms than for the iso-
lated APIs.
disCussioN
Counterfeit medicines are one of the most problematic is-
sues in developing countries, where absence of controls 
tABle 5. stability of samples stored under “standard” condi-
tions for 6 months*
Absorbance variation (%)
active 
pharmaceutical 
ingredient galenic
Paroxetine -1 -5
Amoxicillin -0.3 -6
Hydrocortisone acetate -0.6 +4
Ketoprofen -1 -3
Dextromethorphan hydrobromide -4 -8
Nifedipine -0.3 -0,4
Fluoxetine +0.1 -3
*Results are reported as percentual variation of absorbance values 
(arithmetic mean of 10 analyses) between sample concentration and 
standard.
tABle 6. stability of samples stored under “accelerated” condi-
tions*
Absorbance variation (%) for
t1 (30 d) t2 (60 d) t3 (90 d)
Active pharmaceutical ingredient
paroxetine +1 -4 +8
amoxicillin -2 -11* +17*
hydrocortisone acetate -11* -2 -37*
ketoprofen -13* +1 +22*
dextromethorphan hydrobromide +11* +23* +25*
nifedipine -7 -31* +10
fluoxetine -2 -57* -53*
Galenics:
paroxetine -25* -28* -48*
amoxicillin -3 -11* -28*
hydrocortisone acetate -8 +16* +26*
ketoprofen -13* +2 +39*
dextromethorphan hydrobromide -26* +21* +22*
nifedipine -58* -62* -65*
fluoxetine +22* -56* -56*
*Results are reported as percentual variation of absorbance values 
(arithmetic mean of 10 analyses) between sample concentration and 
standard. out-of-specification values are identified with an asterisk.181 Baratta et al: Diffusion of counterfeit drugs and stability of galenics
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and an adequate pharmacovigilance system causes difficul-
ties in revealing and monitoring the phenomenon and its ef-
fects among the population. Our results were in accordance 
with international data (9,34,35); 2% of tested samples could 
be defined as criminal counterfeits and about 50% as imper-
fect counterfeits, meaning that these drugs could not serve 
their purpose as intended. We used UV-VIS spectroscopy to 
quantify the active pharmaceutical ingredient in each dos-
age form and to carry out the uniformity of content assay. 
UV-VIS spectroscopy was found to be a suitable method 
to comply with European Pharmacopoeia, 7 ed. provisions; 
moreover, it can represent the ideal analytical method to be 
used routinely in developing countries, due to its reduced 
costs and simplicity. It is important to note that European 
Pharmacopoeia, 7 ed. does not define a univocal method 
to be used for content uniformity assay, but refers only to a 
“suitable” method. Cross-check analysis using a HPLC meth-
od demonstrated the consistency of UV-VIS results.
The main target of counterfeiters are highly-priced, life-sav-
ing drugs and this trend is likely to be maintained (3-6,35).
A substandard antibiotic can be even more dangerous 
than other drugs because it can promote the onset of 
bacterial resistances. From the collected data, it is evi-
dent that (even taking into account degradation caused 
by environmental conditions) amoxicillin is widely sub-
ject to counterfeit; a possible explanation for this is the 
high price of this active ingredient (averagely €120/kg), 
which can make it a desirable target for counterfeiters. 
The minor presence of counterfeit ibuprofen (averagely 
€30/kg) and paracetamol (averagely €26/kg) if compared 
to amoxicillin (averagely €120/kg) can be explained by 
their lower prices.
The main limitation of our study is the small number of 
samples;  nevertheless,  since  our  overall  findings  are  in 
good agreement with more vast international studies, we 
deem that useful considerations may arise also from small-
sized surveys such as ours.
In accordance with WHO assessments, India was the first 
exporting country among those examined in the present 
study, with 61 samples (about 50% of which were coun-
terfeits). This prominent role of India in the production of 
counterfeits could be a result of several different causes, 
among which is the permissive legislation and inefficient 
judiciary system, absence of qualified supervising staff, and 
widespread corruption (3).
In the EU, Good Manufacturing Practices are enforced by 
European Medicinal Agency (EMA), while for Asiatic manu-
facturers adherence to Good Manufacturing Practices re-
quirements is more inconsistent, due to the fact that com-
petent authorities audits are often insufficient (36-38).
The second aim of the present study was the stability study 
of common galenic medications and the assessment of their 
use-by date under different environmental conditions..This 
study showed that all the tested dosage forms and active 
substances were stable for 24 months under “standard” con-
ditions (active substance assay within ±10% of nominal val-
ue) in PP containers. Application of “accelerated” and “stress” 
conditions caused a significant degradation if dosage forms 
were stored in PP containers, but results were within speci-
fications after 3 months if samples were stored in glass 
containers in “accelerated” conditions. Since it is common 
practice to consider that 1 month storage under “ac-
celerated” conditions equals to 4 months storage at 
tABle 7. stability results under “accelerated” conditions (AC) and “stress” conditions (sC) for samples stored in glass containers*
Absorbance variation (%)
paroxetine hydrocortisone acetate ketoprofen nifedipine
AC sC AC sC AC sC AC sC
Active pharmaceutical ingredient:
T1 (30 d) +3 +5 +0,5 +1 -1 +14* +1 -42*
T2 (60 d) +3 +17* +0,7 +13* -1,5 +23* +0,6 -47*
T3 (90 d) +2.5 +24* +0.7 +19* +1 +32* +1.5 -52*
Galenics:
T1 (30 d) -1 +6 +0,2 +7 -0,3 +34* -3 -64*
T2 (60 d) -4 +33* +0,6 +18* -0,6 +91* -2 -72*
T3 (90 d) -4.5 +42* +0.8 +59* -0.9 +99* -2.5 -83*
*Results are reported as percentual variation of absorbance values (arithmetic mean of 10 analyses) between sample concentration and standard. 
out-of-specification values are identified with an asterisk.PHARMACOLOGY  182 Croat Med J. 2012;53:173-84
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room temperature, from the results at 3 months a stability at 
ambient conditions of at least 12 months can be extrapolat-
ed. In our opinion, this could represent a good goal because 
the expiration date usually proposed for galenics in the ab-
sence of experimental data are very short.
The  investigation  proved  that  moisture  is  the  principal 
cause of chemical degradation of these APIs and that, as 
a consequence, any step taken to reduce the contact be-
tween environmental moisture and the galenics is likely to 
result in a substantial increase in their stability. Eventually, 
stability results on APIs suggest that the excipient is usually 
the most sensible component of galenic preparations, in a 
degree proportional to its hydrophilic characteristics. This 
hypothesis is supported by the poor stability of ketoprofen 
gel, for which degradation rate was equal to 91% after only 
two months, if compared to the greater stability of hydro-
cortisone cream (degradation rate 18% after two months). 
The above considerations are suggestive of a role of hydro-
philicity of excipients in determining the susceptibility to 
moisture-induced degradation.
Based  on  these  stability  data,  a  minimum  use-by  date 
equal to 24 months under “standard” storage conditions 
(t = 25 ± 2°C, RH = 50 ± 5%) can be proposed for the dosage 
forms investigated during the study. “Accelerated” results 
proved that this minimum period can be safely increased 
according to current European Medicinal Agency guide-
lines. These guidelines give very precise information about 
medicine’s  expiration  date,  which  depends  on  environ-
mental conditions (T and RH) applied during the stability 
tests and on their duration (31,32).
Further  studies  should  be  designed  to  define  the  limit 
shelf-life for these dosage forms, but based on our results it 
is possible to hypothesize that current limits set out by Ital-
ian Pharmacopoeia (maximum 6 months) (22,23) are right-
ly precautionary but excessively restrictive (at least limited 
to the preparations investigated in the present study).
Also in the study of galenics, we demonstrated that UV-
VIS spectroscopy results were comparable and uniform to 
those obtained by HPLC analysis. We deliberately chose 
to use an easy, affordable analytical method such as UV-
VIS spectroscopy in order to mime the work conditions of 
chemist laboratories and to supply pharmacists with use-
ful directions to check the stability of their own galenics.
Our results allow us to prolong the shelf-life of galenics if 
the procedures used to prepare and store the differ-
ent dosage forms follow general principles. It is important 
to note that in developing tropical countries PP containers 
are not suitable both for home and pharmacy storage if the 
space is not air-conditioned; glass is to be preferred in hot 
and moist climates due to the fact that it is able to guarantee 
a longer stability to dosage forms contained.
Irrespective of what type of test is applied (test in “standard” 
or “accelerated” conditions), based on obtained data and 
provided that galenics are prepared using written standard 
procedures and starting materials of sufficient quality, it is 
reasonable to increase the use-by date of dosage forms 
compared to that suggested by Pharmacopoeia. This rep-
resents an important step for the organization of the ga-
lenic laboratory. It would be easier to plan preparation ac-
tivity satisfying both the medicine request of the hospital 
and the operative time of the technicians engaged.
In  conclusion,  the  achieved  results  highlighted  the  im-
portance of our Project to help the production of galenics 
complying with quality requirements, especially in those 
countries where people are most vulnerable to counterfeit 
drugs, which threaten their health and their faith in mod-
ern medicine.
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